Form 4 for APUS Apimeds Pharmaceuticals US, Inc.
Accepted 2025-05-20 00:00:00 ET · period of report 2025-05-16 · accession 0001474506-25-000099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-20 | 2025-05-16 | APUS | Emerson Erik C. | CEO, Dir | A - Grant | $0.00 | +750.0K | 750.0K | New | $0 |
| D | 2025-05-20 | 2025-05-16 | APUS | Emerson Erik C. | CEO, Dir | A - Grant | $0.00 | +347.3K | 347.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.01 per share | 2025-05-16 | A | A | 750,000 | $0.00 | 750,000 | D | — | — | |
| 2 | Derivative | Stock option (right to buy) | 2025-05-16 | A | A | 347,279 | $0.00 | 347,279 | D | $1.81 · — to 2035-05-16 | 347,279 Common Stock, par value $0.01 per share | (F1) Forty percent (40%) of the options vested immediately upon grant, and the remainder will vest in three equal annual installments beginning on 05/16/2026. The reporting person has agreed not to sell any shares underlying the options, even if exercised, for a period of three years from the date of grant. |